Table 1.
List of the studies of interferonopathy patient-derived iPS cells
| Author (Ref) | Disease | Gene | iPS cell-derived cell types | Key findings |
|---|---|---|---|---|
| Genova et al. [29] | AGS | TREX1, RANSEH2B, IFIH1 | iPS cells | Differences in drug cytotoxicity of drugs due to genetic mutations |
| Ferraroet al. [30] | AGS | TREX1 | iPS cells | iPS cell establishment |
| Ferraro et al. [31] | AGS | RNASEH2B | iPS cells | iPS cell establishment |
| Masneri et al. [32] | AGS | IFIH1 | iPS cells | iPS cell establishment |
| Fuchs et al. [33] | AGS | SAMHD1 | iPS cells | iPS cell establishment |
| Hanchen et al. [34] | AGS | SAMHD1 | iPS cells | iPS cell establishment |
| Hanchen et al. [35] | AGS | TREX1 | iPS cells | iPS cell establishment |
| Barnabei et al. [36] | SAVI | STING | iPS cells | iPS cell establishment |
| Mehta et al. [37] | SAVI | STING | iPS cells | iPS cell establishment |
| Honda-Ozaki et al. [38] | NNS | PMSB8 | Myeloid cells | Pro-inflammatory cytokine overexpression via reactive oxygen species and p38 MAPK |
| Kase et al. [39] | NNS | PMSB8 | Myeloid cells | Drug screening for inhibiting pro-inflammatory chemokine secretion |
References and abbreviations are the same as the main document